Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Cancers|August 26, 2023
Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer TherapyMark Sutherland, Andrew Gordon, Fatemah O F O Al-Shammari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2016
Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant ProgressionHeather Nesbitt, Niall M Byrne, S Nicole Williams, et al.
Bioorganic & Medicinal Chemistry|May 1, 2021
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compoundsNatalia Ortuzar, Kersti Karu, Daniela Presa, et al.
Cancer Research|July 29, 2010
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinasesJennifer M Atkinson, Robert A Falconer, Dylan R Edwards, et al.
RSC Medicinal Chemistry|September 16, 2024
Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonistsAdam Throup, Manar Saleh Zraikat, Andrew Gordon, et al.
Molecular Cancer Therapeutics|October 4, 2012
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladderMark Sutherland, Jason H Gill, Paul M Loadman, et al.
Biochemical Pharmacology|March 6, 2012
Minor structural modifications to alchemix influence mechanism of action and pharmacological activityQasem M A Abdallah, Roger M Phillips, Fredrik Johansson, et al.
Scientific Reports|September 24, 2021
Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancerDaniela Presa, Syed A Khurram, Amir Z A Zubir, et al.
Journal of Medicinal Chemistry|July 13, 2013
Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activityHelen M Sheldrake, Sandra Travica, Inger Johansson, et al.
Plos One|August 17, 2013
Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migrationYousef M J Al-Saraireh, Mark Sutherland, Bradley R Springett, et al.
Pageof 6